Model‐informed drug development for immuno‐oncology agonistic anti‐GITR antibody GWN323: Dose selection based on MABEL and biologically active dose

• Главные авторы: Yan Ji (Автор), Deborah Knee (Автор), Xinhui Chen (Автор), Anhthu Dang (Автор), Jennifer Mataraza (Автор), Babette Wolf (Автор), Sherwin K. B. Sy (Автор)
• Формат: ‌
• Опубликовано: Wiley, 2022-09-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract GWN323, an agonistic human anti‐GITR (glucocorticoid‐induced TNFR‐related protein) IgG1 antibody, was studied clinically as an immuno‐oncology therapeutic agent. A model‐based minimum anticipated biological effect level (MABEL) approach integrating in vitro and in vivo data informed dose se...